Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 66 Records) |
| Query Trace: Neoplasms and CYP17A1[original query] |
|---|
| CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss. Journal of molecular endocrinology 2015 Aug 55 (1): 69-79. Rodríguez-Sanz M, García-Giralt N, Prieto-Alhambra D, Servitja S, Balcells S, Pecorelli R, Díez-Pérez A, Grinberg D, Tusquets I, Nogués |
| Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International journal of molecular sciences 2016 17 (7): . Binder Moritz, Zhang Ben Y, Hillman David W, Kohli Rhea, Kohli Tanvi, Lee Adam, Kohli Mani |
| Association of the CYP17-34T/C Polymorphism with Pancreatic Cancer Risk. Asian Pacific journal of cancer prevention : APJCP 2016 17 Spec No. 71-5. Hussain Shahid, Bano Raisa, Tahir Khan Muhammad, Haroon Khan Mohamm |
| CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. The International journal of biological markers 2016 Feb 0. Salvi Samanta, Casadio Valentina, Burgio Salvatore Luca, Conteduca Vincenza, Rossi Lorena, Menna Cecilia, Carretta Elisa, Costantini Matteo, Zoli Wainer, Giorgi Ugo |
| Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups. International journal of clinical and experimental medicine 2015 8 (10): 19232-40. Poniah Prevathe, Mohamed Zahurin, Apalasamy Yamunah Devi, Mohd Zain Shamsul, Kuppusamy Shanggar, Razack Azad |
| Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics 2017 Jun . Sini Valentina, Botticelli Andrea, Lunardi Gianluigi, Gori Stefania, Marchetti Pao |
| Polymorphism in xenobiotic and estrogen metabolizing genes, exposure to perfluorinated compounds and subsequent breast cancer risk: A nested case-control study in the Danish National Birth Cohort. Environmental research 2017 Jan 154 325-333. Ghisari Mandana, Long Manhai, Røge Durita Mohr, Olsen Jørn, Bonefeld-Jørgensen Eva |
| HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nature reviews. Urology 2017 12 15 (3): 191-196. Hettel Daniel, Sharifi Ni |
| Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 2017 Dec . Tang Li, Platek Mary E, Yao Song, Till Cathee, Goodman Phyllis J, Tangen Catherine M, Wu Yue, Platz Elizabeth A, Neuhouser Marian L, Stanczyk Frank Z, Reichardt Juergen K V, Santella Regina M, Hsing Ann, Figg William D, Lippman Scott M, Thompson Ian M, Ambrosone Christine |
| Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness. PloS one 2017 12 (10): e0185447. Robles-Fernandez Inmaculada, Martinez-Gonzalez Luis Javier, Pascual-Geler Manrique, Cozar Jose Manuel, Puche-Sanz Ignacio, Serrano Maria Jose, Lorente Jose Antonio, Alvarez-Cubero Maria Jes |
| HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA oncology 2017 10 4 (4): 554-557. Almassi Nima, Reichard Chad, Li Jianbo, Russell Carly, Perry Jaselle, Ryan Charles J, Friedlander Terence, Sharifi Ni |
| TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clinical pharmacology and therapeutics 2017 10 104 (1): 201-210. Qin Sisi, Liu Duan, Kohli Manish, Wang Liguo, Vedell Peter T, Hillman David W, Niu Nifang, Yu Jia, Weinshilboum Richard M, Wang Liew |
| HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. The Journal of clinical investigation 2018 6 128 (8): 3333-3340. Alyamani Mohammad, Emamekhoo Hamid, Park Sunho, Taylor Jennifer, Almassi Nima, Upadhyay Sunil, Tyler Allison, Berk Michael P, Hu Bo, Hwang Tae Hyun, Figg William Douglas, Peer Cody J, Chien Caly, Koshkin Vadim S, Mendiratta Prateek, Grivas Petros, Rini Brian, Garcia Jorge, Auchus Richard J, Sharifi Ni |
| Genetic Variations, Exposure to Persistent Organic Pollutants and Breast Cancer Risk - A Greenlandic Case-Control Study. Basic & clinical pharmacology & toxicology 2018 Mar . Wielsøe Maria, Eiberg Hans, Ghisari Mandana, Kern Peder, Lind Ole, Bonefeld-Jørgensen Eva Cecil |
| The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition. General physiology and biophysics 2018 1 36 (5): 487-499. Kme?ová Sivo?ová Monika, Jure?eková Jana, Tatarková Zuzana, Kaplán Peter, Lichardusová Lucia, Hatok Joz |
| Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. Endocrine connections 2019 Jul . Rizzolo Piera, Silvestri Valentina, Valentini Virginia, Zelli Veronica, Bucalo Agostino, Zanna Ines, Bianchi Simonetta, Tibiletti Maria Grazia, Russo Antonio, Varesco Liliana, Tedaldi Gianluca, Bonanni Bernardo, Azzollini Jacopo, Manoukian Siranoush, Coppa Anna, Giannini Giuseppe, Cortesi Laura, Viel Alessandra, Montagna Marco, Peterlongo Paolo, Radice Paolo, Palli Domenico, Ottini Lau |
| CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. Cancer chemotherapy and pharmacology 2020 Sep . Crucitta Stefania, Del Re Marzia, Paolieri Federico, Bloise Francesco, Sbrana Andrea, Sammarco Enrico, Mercinelli Chiara, Cucchiara Federico, Fontanelli Lorenzo, Galli Luca, Danesi Roma |
| Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy. Urologic oncology 2020 7 38 (11): 849.e11-849.e18. Shiota Masaki, Endo Satoshi, Fujimoto Naohiro, Tsukahara Shigehiro, Ushijima Miho, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Uchiumi Takeshi, Eto Masatos |
| Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients. Pharmacogenomics and personalized medicine 2020 6 13 181-188. Wu Xiang, Xu Qing-Jiang, Chen Ping-Zhou, Yu Chen-Bo, Ye Lie-Fu, Li T |
| Genetic variants in xenobiotic detoxification enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer. The Science of the total environment 2020 5 730 138314. Martinez-Gonzalez L J, Antúnez-Rodríguez A, Vazquez-Alonso F, Hernandez A F, Alvarez-Cubero M |
| Urinary bisphenol A and its interaction with CYP17A1 rs743572 are associated with breast cancer risk. Chemosphere 2021 Aug 286 (Pt 3): 131880. He Heng, Deng Yao, Wan Hao, Shen Na, Li Jiaoyuan, Zeng Qiang, Chang Jiang, Lu Qing, Miao Xiaoping, Tian Jianbo, Zhong Ro |
| Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. Frontiers in genetics 2021 12 662734. Hertz Daniel L, Smith Karen Lisa, Zong Yuhua, Gersch Christina L, Pesch Andrea M, Lehman Jennifer, Blackford Amanda L, Henry N Lynn, Kidwell Kelley M, Rae James M, Stearns Ver |
| Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview. American journal of cancer research 2021 6 11 (5): 1873-1894. Liu Min, Shi Hongzhe, Yan Jiaqing, Zhang Yuan, Ma Yinglin, Le Kaidi, Li Zhongdong, Xing Nianzeng, Li Guoh |
| Variable expression quantitative trait loci analysis of breast cancer risk variants. Scientific reports 2021 3 11 (1): 7192. Wiggins George A R, Black Michael A, Dunbier Anita, Merriman Tony R, Pearson John F, Walker Logan |
| The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. The pharmacogenomics journal 2021 3 21 (4): 440-445. Shiota Masaki, Akamatsu Shusuke, Narita Shintaro, Sumiyoshi Takayuki, Fujiwara Maki, Uchiumi Takeshi, Ogawa Osamu, Habuchi Tomonori, Eto Masatos |
| Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer. The Science of the total environment 2022 6 843 156965. Martin-Way D, Puche-Sanz I, Cozar J M, Zafra-Gomez A, Gomez-Regalado M D C, Morales-Alvarez C M, Hernandez A F, Martinez-Gonzalez L J, Alvarez-Cubero M |
| The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer. Urologic oncology 2022 4 40 (5): 198.e1-198.e8. Gakis Georgios, Perner Sven, Stenzl Arnulf, Renninger Mark |
| A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma. Frontiers in cell and developmental biology 2022 3 10 730132. Zhang Kai, Qian Ying, Quan Xiaowei, Zhu Tengteng, Qian Biy |
| Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics 2023 2 15 (2): . Ferrero Jean-Marc, Mahammedi Hakim, Gravis Gwenaelle, Roubaud Guilhem, Beuzeboc Philippe, Largillier Remi, Borchiellini Delphine, Linassier Claude, Ebran Nathalie, Pace-Loscos Tanguy, Etienne-Grimaldi Marie-Christine, Schiappa Renaud, Gal Jocelyn, Milano Géra |
| A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 11 169 115890. Stefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J H Coenen, Andries M Bergman, Stijn L W Koolen, Ronald de Wit, Alwin D R Huitema, Ron H N van Schaik, Ron H J Mathijss |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: